{
  "doc_id": "38",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "《中国高尿酸血症相关疾病诊疗多学科专家共识》解读",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "《中国高尿酸血症相关疾病诊疗多学科专家共识》解读",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "高尿酸血症",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Hyperuricemia"
            }
          ],
          "relations": [],
          "sentence_en": "Interpretation of \"Chinese Multidisciplinary Expert Consensus on Diagnosis and Treatment of Hyperuricemia-Related Diseases\""
        }
      ],
      "paragraph_en": "Interpretation of \"Chinese Multidisciplinary Expert Consensus on Diagnosis and Treatment of Hyperuricemia-Related Diseases\""
    },
    {
      "paragraph_id": "1",
      "paragraph": "高尿酸血症(HUA)的流行总体呈现逐年升高的趋势，常与高血压、高脂血症、2型糖尿病、肥胖、胰岛素抵抗等传统的代谢性心血管危险因素伴发，因此长期以来HUA仅仅被认为是代谢异常的一种标志。但近年来多个前瞻性大规模临床结果显示，HUA是心血管疾病、糖尿病的独立危险因素，也是全因死亡、总心血管事件和缺血性卒中的独立危险因素。HUA可增加糖尿病肾病的风险，是急慢性肾衰竭的强有力的预测因素。在此背景下，风湿免疫、肾脏、内分泌代谢、心血管、神经、泌尿和中医科等学科专家组成的HUA相关疾病诊疗多学科共识专家组，经过充分讨论制定出《中国高尿酸血症相关疾病诊疗多学科专家共识》，并于发布在《中华内科杂志》2017年第3期上，该专家共识旨在推动多学科协作，指导和规范HUA相关疾病的临床实践。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "高尿酸血症(HUA)的流行总体呈现逐年升高的趋势，常与高血压、高脂血症、2型糖尿病、肥胖、胰岛素抵抗等传统的代谢性心血管危险因素伴发，因此长期以来HUA仅仅被认为是代谢异常的一种标志。但近年来多个前瞻性大规模临床结果显示，HUA是心血管疾病、糖尿病的独立危险因素，也是全因死亡、总心血管事件和缺血性卒中的独立危险因素。HUA可增加糖尿病肾病的风险，是急慢性肾衰竭的强有力的预测因素。",
          "start_idx": 0,
          "end_idx": 191,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "高尿酸血症(HUA)",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 10,
              "entity_en": "Hyperuricemia (HUA)"
            },
            {
              "entity_id": "T2",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T3",
              "entity": "高脂血症",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 35,
              "entity_en": "Hyperlipidemia"
            },
            {
              "entity_id": "T4",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 41,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T5",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 36,
              "end_idx": 38,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T6",
              "entity": "胰岛素抵抗",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 50,
              "entity_en": "Insulin resistance"
            },
            {
              "entity_id": "T7",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T8",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 73,
              "end_idx": 76,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T9",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 114,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T10",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 115,
              "end_idx": 120,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T11",
              "entity": "缺血性卒中",
              "entity_type": "Disease",
              "start_idx": 146,
              "end_idx": 151,
              "entity_en": "Ischemic stroke"
            },
            {
              "entity_id": "T12",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 159,
              "end_idx": 162,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T13",
              "entity": "急慢性肾衰竭",
              "entity_type": "Disease",
              "start_idx": 175,
              "end_idx": 181,
              "entity_en": "Acute and chronic renal failure"
            },
            {
              "entity_id": "T17",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 178,
              "end_idx": 179,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T18",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 168,
              "end_idx": 169,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T19",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 121,
              "end_idx": 124,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T20",
              "entity": "高尿酸血症(HUA)",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 10,
              "entity_en": "Hyperuricemia (HUA)"
            },
            {
              "entity_id": "T21",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 115,
              "end_idx": 118,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T22",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 165,
              "end_idx": 170,
              "entity_en": "Diabetic nephropathy"
            },
            {
              "entity_id": "T23",
              "entity": "全因死亡",
              "entity_type": "Disease",
              "start_idx": 134,
              "end_idx": 138,
              "entity_en": "All-cause death"
            },
            {
              "entity_id": "T24",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 140,
              "end_idx": 145,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T25",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 140,
              "end_idx": 143,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R0",
              "head_entity_id": "T5",
              "tail_entity_id": "T4"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R1",
              "head_entity_id": "T21",
              "tail_entity_id": "T10"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R2",
              "head_entity_id": "T17",
              "tail_entity_id": "T13"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R3",
              "head_entity_id": "T18",
              "tail_entity_id": "T22"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R4",
              "head_entity_id": "T25",
              "tail_entity_id": "T24"
            }
          ],
          "sentence_en": "The prevalence of hyperuricemia (HUA) has generally shown an increasing trend year by year. It is often associated with traditional metabolic cardiovascular risk factors such as hypertension, hyperlipidemia, type 2 diabetes, obesity, and insulin resistance. Therefore, HUA has long been considered merely a sign of metabolic abnormalities. However, in recent years, multiple prospective large-scale clinical results have shown that HUA is an independent risk factor for cardiovascular disease and diabetes, as well as an independent risk factor for all-cause mortality, total cardiovascular events, and ischemic stroke. HUA can increase the risk of diabetic nephropathy and is a strong predictor of acute and chronic renal failure."
        },
        {
          "sentence_id": "1",
          "sentence": "在此背景下，风湿免疫、肾脏、内分泌代谢、心血管、神经、泌尿和中医科等学科专家组成的HUA相关疾病诊疗多学科共识专家组，经过充分讨论制定出《中国高尿酸血症相关疾病诊疗多学科专家共识》，并于发布在《中华内科杂志》2017年第3期上，该专家共识旨在推动多学科协作，指导和规范HUA相关疾病的临床实践。",
          "start_idx": 191,
          "end_idx": 338,
          "entities": [
            {
              "entity_id": "T14",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 44,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T15",
              "entity": "高尿酸血症",
              "entity_type": "Disease",
              "start_idx": 71,
              "end_idx": 76,
              "entity_en": "Hyperuricemia"
            },
            {
              "entity_id": "T16",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 134,
              "end_idx": 137,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "In this context, a multidisciplinary consensus expert group on the diagnosis and treatment of HUA-related diseases, composed of experts in rheumatology and immunology, nephrology, endocrine metabolism, cardiovascular, neurology, urology and traditional Chinese medicine, formulated the \"Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia-Related Diseases\" after full discussion and published it in the \"Chinese Journal of Internal Medicine\" Issue 3, 2017. This expert consensus aims to promote multidisciplinary collaboration and guide and standardize the clinical practice of HUA-related diseases."
        }
      ],
      "paragraph_en": "The prevalence of hyperuricemia (HUA) has generally shown an increasing trend year by year. It is often associated with traditional metabolic cardiovascular risk factors such as hypertension, hyperlipidemia, type 2 diabetes, obesity, and insulin resistance. Therefore, HUA has long been considered a sign of metabolic abnormalities. However, in recent years, multiple prospective large-scale clinical results have shown that HUA is an independent risk factor for cardiovascular disease and diabetes, as well as an independent risk factor for all-cause mortality, total cardiovascular events, and ischemic stroke. HUA can increase the risk of diabetic nephropathy and is a strong predictor of acute and chronic renal failure. In this context, the multidisciplinary consensus expert group on the diagnosis and treatment of HUA-related diseases, composed of experts in rheumatology and immunology, kidney, endocrine metabolism, cardiovascular, neurology, urology, and traditional Chinese medicine, has formulated the \"Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia-Related Diseases\" after full discussion and published it in the 3rd issue of the Chinese Journal of Internal Medicine in 2017. This expert consensus aims to promote multidisciplinary collaboration and guide and standardize the clinical practice of HUA-related diseases."
    },
    {
      "paragraph_id": "2",
      "paragraph": "HUA的定义",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "HUA的定义",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [
            {
              "entity_id": "T26",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "Definition of HUA"
        }
      ],
      "paragraph_en": "Definition of HUA"
    },
    {
      "paragraph_id": "4",
      "paragraph": "HUA的流行病学特征",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "HUA的流行病学特征",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T27",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "Epidemiological characteristics of HUA"
        }
      ],
      "paragraph_en": "Epidemiological characteristics of HUA"
    },
    {
      "paragraph_id": "5",
      "paragraph": "血尿酸水平受年龄、性别、种族、遗传、饮食习惯、药物、环境等多种因素影响，我国目前尚缺乏全国范围的HUA流行病学调查资料。来自不同时间、地区的资料显示，目前我国HUA呈现高流行、年轻化、男性高于女性、沿海高于内陆的流行趋势，原因可能与人群饮食结构、平均寿命的延长和医疗保健水平的不断提高有关。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "血尿酸水平受年龄、性别、种族、遗传、饮食习惯、药物、环境等多种因素影响，我国目前尚缺乏全国范围的HUA流行病学调查资料。来自不同时间、地区的资料显示，目前我国HUA呈现高流行、年轻化、男性高于女性、沿海高于内陆的流行趋势，原因可能与人群饮食结构、平均寿命的延长和医疗保健水平的不断提高有关。",
          "start_idx": 0,
          "end_idx": 145,
          "entities": [
            {
              "entity_id": "T28",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T29",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T30",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 82,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T31",
              "entity": "人群饮食结构",
              "entity_type": "Reason",
              "start_idx": 116,
              "end_idx": 122,
              "entity_en": "Dietary structure of the population"
            },
            {
              "entity_id": "T32",
              "entity": "平均寿命的延长",
              "entity_type": "Reason",
              "start_idx": 123,
              "end_idx": 130,
              "entity_en": "Increased life expectancy"
            },
            {
              "entity_id": "T33",
              "entity": "医疗保健水平的不断提高",
              "entity_type": "Reason",
              "start_idx": 131,
              "end_idx": 142,
              "entity_en": "The continuous improvement of medical care"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R5",
              "head_entity_id": "T28",
              "tail_entity_id": "T29"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R6",
              "head_entity_id": "T31",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R7",
              "head_entity_id": "T32",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R8",
              "head_entity_id": "T33",
              "tail_entity_id": "T30"
            }
          ],
          "sentence_en": "Serum uric acid levels are affected by many factors, including age, gender, race, genetics, dietary habits, drugs, and environment. my country currently lacks nationwide epidemiological survey data on HUA. Data from different times and regions show that HUA in my country is currently highly prevalent, younger, with a higher prevalence in men than in women, and a higher prevalence in coastal areas than inland areas. The reasons may be related to the dietary structure of the population, the extension of average life expectancy, and the continuous improvement of medical care levels."
        }
      ],
      "paragraph_en": "Serum uric acid levels are affected by many factors, including age, gender, race, genetics, dietary habits, drugs, and environment. my country currently lacks nationwide epidemiological survey data on HUA. Data from different times and regions show that HUA in my country is currently highly prevalent, younger, with a higher prevalence in men than in women, and a higher prevalence in coastal areas than inland areas. The reasons may be related to the dietary structure of the population, the extension of average life expectancy, and the continuous improvement of medical care levels."
    },
    {
      "paragraph_id": "6",
      "paragraph": "HUA及痛风的诊断",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "HUA及痛风的诊断",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T34",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T35",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "gout"
            }
          ],
          "relations": [],
          "sentence_en": "Diagnosis of HUA and gout"
        }
      ],
      "paragraph_en": "Diagnosis of HUA and gout"
    },
    {
      "paragraph_id": "7",
      "paragraph": "共识明确提出，正常饮食下，非同日两次空腹血尿酸水平>420μmol/L即可诊断为HUA。同时指出，年龄<25岁、具有痛风家族史的HUA患者需排查遗传性嘌呤代谢异常疾病。关于痛风的诊断既往多采用1977年美国风湿病学会(ACR)痛风分类标准。近年来，关节B超检查和双能CT检查逐渐普及，共识建议采用2015年ACR/欧洲抗风湿病联盟(EULAR)提出的ACR/EULAR痛风分类标准，新标准不仅可用于痛风急性发作期的诊断分类，同时也可应用于间歇期痛风患者的分类，能够真正有效地将痛风从其他疾病中区分出来，从而更好地进行临床研究和药物临床试验。新的标准将影像学诊断纳入评分体系中，体现了对新的影像技术的肯定，但由于关节超声检查易受操作者技术水平影响，超声及双能CT的迅速推广也给痛风的诊断带来新的挑战。因此，规范、可靠的影像学诊断十分必要。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "共识明确提出，正常饮食下，非同日两次空腹血尿酸水平>420μmol/L即可诊断为HUA。同时指出，年龄<25岁、具有痛风家族史的HUA患者需排查遗传性嘌呤代谢异常疾病。关于痛风的诊断既往多采用1977年美国风湿病学会(ACR)痛风分类标准。近年来，关节B超检查和双能CT检查逐渐普及，共识建议采用2015年ACR/欧洲抗风湿病联盟(EULAR)提出的ACR/EULAR痛风分类标准，新标准不仅可用于痛风急性发作期的诊断分类，同时也可应用于间歇期痛风患者的分类，能够真正有效地将痛风从其他疾病中区分出来，从而更好地进行临床研究和药物临床试验。新的标准将影像学诊断纳入评分体系中，体现了对新的影像技术的肯定，但由于关节超声检查易受操作者技术水平影响，超声及双能CT的迅速推广也给痛风的诊断带来新的挑战。",
          "start_idx": 0,
          "end_idx": 349,
          "entities": [
            {
              "entity_id": "T36",
              "entity": "空腹血尿酸",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Fasting serum uric acid"
            },
            {
              "entity_id": "T37",
              "entity": ">420μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 25,
              "end_idx": 35,
              "entity_en": ">420μmol/L"
            },
            {
              "entity_id": "T38",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T39",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 60,
              "entity_en": "gout"
            },
            {
              "entity_id": "T40",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 67,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T41",
              "entity": "遗传性嘌呤代谢异常",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 81,
              "entity_en": "Inherited disorders of purine metabolism"
            },
            {
              "entity_id": "T42",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 88,
              "entity_en": "gout"
            },
            {
              "entity_id": "T43",
              "entity": "风湿病",
              "entity_type": "Disease",
              "start_idx": 103,
              "end_idx": 106,
              "entity_en": "Rheumatism"
            },
            {
              "entity_id": "T44",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 113,
              "end_idx": 115,
              "entity_en": "gout"
            },
            {
              "entity_id": "T45",
              "entity": "B超",
              "entity_type": "Test",
              "start_idx": 126,
              "end_idx": 128,
              "entity_en": "B-ultrasound"
            },
            {
              "entity_id": "T46",
              "entity": "风湿病",
              "entity_type": "Disease",
              "start_idx": 160,
              "end_idx": 163,
              "entity_en": "Rheumatism"
            },
            {
              "entity_id": "T47",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 184,
              "end_idx": 186,
              "entity_en": "gout"
            },
            {
              "entity_id": "T48",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 199,
              "end_idx": 201,
              "entity_en": "gout"
            },
            {
              "entity_id": "T49",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 222,
              "end_idx": 224,
              "entity_en": "gout"
            },
            {
              "entity_id": "T50",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 238,
              "end_idx": 240,
              "entity_en": "gout"
            },
            {
              "entity_id": "T51",
              "entity": "关节超声",
              "entity_type": "Test",
              "start_idx": 305,
              "end_idx": 309,
              "entity_en": "Joint Ultrasound"
            },
            {
              "entity_id": "T52",
              "entity": "超声",
              "entity_type": "Test",
              "start_idx": 323,
              "end_idx": 325,
              "entity_en": "Ultrasound"
            },
            {
              "entity_id": "T53",
              "entity": "双能CT",
              "entity_type": "Test",
              "start_idx": 326,
              "end_idx": 330,
              "entity_en": "Dual-energy CT"
            },
            {
              "entity_id": "T54",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 337,
              "end_idx": 339,
              "entity_en": "gout"
            },
            {
              "entity_id": "T55",
              "entity": "双能CT",
              "entity_type": "Test",
              "start_idx": 131,
              "end_idx": 135,
              "entity_en": "Dual-energy CT"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R9",
              "head_entity_id": "T36",
              "tail_entity_id": "T38"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R10",
              "head_entity_id": "T45",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R11",
              "head_entity_id": "T55",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R12",
              "head_entity_id": "T51",
              "tail_entity_id": "T54"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R13",
              "head_entity_id": "T52",
              "tail_entity_id": "T54"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R14",
              "head_entity_id": "T53",
              "tail_entity_id": "T54"
            }
          ],
          "sentence_en": "The consensus clearly states that under normal diet, fasting blood uric acid levels >420 μmol/L on two different days can be diagnosed as HUA. It also points out that HUA patients aged <25 years with a family history of gout need to be screened for hereditary purine metabolism disorders. In the past, the diagnosis of gout was mostly based on the 1977 American College of Rheumatology (ACR) gout classification criteria. In recent years, joint ultrasound examination and dual-energy CT examination have gradually become popular. The consensus recommends the use of the ACR/EULAR gout classification criteria proposed by the ACR/European League Against Rheumatism (EULAR) in 2015. The new criteria can not only be used for the diagnosis and classification of acute gout attacks, but also for the classification of intermittent gout patients. It can truly and effectively distinguish gout from other diseases, so as to better conduct clinical research and drug clinical trials. The new standard incorporates imaging diagnosis into the scoring system, which reflects the affirmation of new imaging technology. However, since joint ultrasound examination is easily affected by the operator's technical level, the rapid promotion of ultrasound and dual-energy CT also brings new challenges to the diagnosis of gout."
        },
        {
          "sentence_id": "1",
          "sentence": "因此，规范、可靠的影像学诊断十分必要。",
          "start_idx": 349,
          "end_idx": 368,
          "entities": [],
          "relations": [],
          "sentence_en": "Therefore, standardized and reliable imaging diagnosis is very necessary."
        }
      ],
      "paragraph_en": "The consensus clearly states that under a normal diet, fasting blood uric acid levels >420 μmol/L on two different days can be diagnosed as HUA. It also points out that HUA patients aged <25 years with a family history of gout need to be screened for hereditary purine metabolism disorders. In the past, the diagnosis of gout was mostly based on the 1977 American College of Rheumatology (ACR) gout classification criteria. In recent years, joint B-ultrasound examination and dual-energy CT examination have gradually become popular. The consensus recommends the use of the ACR/EULAR gout classification criteria proposed by the ACR/European League Against Rheumatism (EULAR) in 2015. The new criteria can not only be used for the diagnosis and classification of acute gout attacks, but also for the classification of intermittent gout patients. It can truly and effectively distinguish gout from other diseases, thereby better conducting clinical research and drug clinical trials. The new standard incorporates imaging diagnosis into the scoring system, reflecting the affirmation of new imaging technology. However, since joint ultrasound examination is easily affected by the operator's technical level, the rapid promotion of ultrasound and dual-energy CT also brings new challenges to the diagnosis of gout. Therefore, standardized and reliable imaging diagnosis is very necessary."
    },
    {
      "paragraph_id": "8",
      "paragraph": "HUA的危害性",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "HUA的危害性",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [
            {
              "entity_id": "T56",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "The harmfulness of HUA"
        }
      ],
      "paragraph_en": "The harmfulness of HUA"
    },
    {
      "paragraph_id": "9",
      "paragraph": "尿酸来源部分由人体摄入，部分由体内分解代谢的嘌呤化合物在肝脏中产生，三分之二通过肾脏排泄，其余由消化道、皮肤汗腺等排泄。正常情况下，体内尿酸产生和排泄保持动态平衡，凡导致尿酸生成过多和/或排泄减少的因素均可导致HUA。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "尿酸来源部分由人体摄入，部分由体内分解代谢的嘌呤化合物在肝脏中产生，三分之二通过肾脏排泄，其余由消化道、皮肤汗腺等排泄。正常情况下，体内尿酸产生和排泄保持动态平衡，凡导致尿酸生成过多和/或排泄减少的因素均可导致HUA。",
          "start_idx": 0,
          "end_idx": 109,
          "entities": [
            {
              "entity_id": "T57",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T58",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 68,
              "end_idx": 70,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T59",
              "entity": "尿酸生成过多",
              "entity_type": "Reason",
              "start_idx": 85,
              "end_idx": 91,
              "entity_en": "Excessive production of uric acid"
            },
            {
              "entity_id": "T60",
              "entity": "排泄减少",
              "entity_type": "Reason",
              "start_idx": 94,
              "end_idx": 98,
              "entity_en": "Reduced excretion"
            },
            {
              "entity_id": "T61",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 108,
              "entity_en": "HUA"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R15",
              "head_entity_id": "T58",
              "tail_entity_id": "T61"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R16",
              "head_entity_id": "T59",
              "tail_entity_id": "T61"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R17",
              "head_entity_id": "T60",
              "tail_entity_id": "T61"
            }
          ],
          "sentence_en": "Uric acid is partly ingested by the human body, partly produced in the liver by purine compounds metabolized in the body, two-thirds excreted through the kidneys, and the rest excreted through the digestive tract, skin sweat glands, etc. Under normal circumstances, the production and excretion of uric acid in the body maintain a dynamic balance, and any factor that causes excessive uric acid production and/or reduced excretion can lead to HUA."
        }
      ],
      "paragraph_en": "Uric acid is partly ingested by the human body, partly produced in the liver by purine compounds metabolized in the body, two-thirds excreted through the kidneys, and the rest excreted through the digestive tract, skin sweat glands, etc. Under normal circumstances, the production and excretion of uric acid in the body maintain a dynamic balance, and any factor that causes excessive uric acid production and/or reduced excretion can lead to HUA."
    },
    {
      "paragraph_id": "10",
      "paragraph": "HUA的危害性越来越受到重视。当血尿酸超过饱和浓度，尿酸盐晶体析出可直接黏附、沉积于关节及周围软组织、肾小管和血管等部位，趋化中性粒细胞和巨噬细胞；细胞与晶体相互作用后释放致炎因子、金属蛋白酶9、水解酶等，导致关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤，故普遍认为HUA是多种心血管危险因素及相关疾病(代谢综合征、2型糖尿病、高血压、心血管事件及死亡、慢性肾病等)的独立危险因素。共识明确指出，HUA是痛风发生的最重要生化基础和最直接的病因，痛风性关节炎患者首先遵循HUA管理原则。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "HUA的危害性越来越受到重视。当血尿酸超过饱和浓度，尿酸盐晶体析出可直接黏附、沉积于关节及周围软组织、肾小管和血管等部位，趋化中性粒细胞和巨噬细胞；细胞与晶体相互作用后释放致炎因子、金属蛋白酶9、水解酶等，导致关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤，故普遍认为HUA是多种心血管危险因素及相关疾病(代谢综合征、2型糖尿病、高血压、心血管事件及死亡、慢性肾病等)的独立危险因素。共识明确指出，HUA是痛风发生的最重要生化基础和最直接的病因，痛风性关节炎患者首先遵循HUA管理原则。",
          "start_idx": 0,
          "end_idx": 244,
          "entities": [
            {
              "entity_id": "T62",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T63",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T64",
              "entity": "致炎因子",
              "entity_type": "Reason",
              "start_idx": 86,
              "end_idx": 90,
              "entity_en": "Inflammatory factors"
            },
            {
              "entity_id": "T65",
              "entity": "金属蛋白酶9",
              "entity_type": "Reason",
              "start_idx": 91,
              "end_idx": 97,
              "entity_en": "Metalloproteinase 9"
            },
            {
              "entity_id": "T66",
              "entity": "水解酶",
              "entity_type": "Reason",
              "start_idx": 98,
              "end_idx": 101,
              "entity_en": "Hydrolases"
            },
            {
              "entity_id": "T67",
              "entity": "关节软骨、骨质、肾脏以及血管内膜等急慢性炎症损伤",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 129,
              "entity_en": "Acute and chronic inflammatory damage to joint cartilage, bone, kidney, and vascular endothelium"
            },
            {
              "entity_id": "T68",
              "entity": "关节软骨",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 109,
              "entity_en": "Articular cartilage"
            },
            {
              "entity_id": "T69",
              "entity": "骨质",
              "entity_type": "Anatomy",
              "start_idx": 110,
              "end_idx": 112,
              "entity_en": "Bone"
            },
            {
              "entity_id": "T70",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 113,
              "end_idx": 115,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T71",
              "entity": "血管内膜",
              "entity_type": "Anatomy",
              "start_idx": 117,
              "end_idx": 121,
              "entity_en": "Vascular lining"
            },
            {
              "entity_id": "T72",
              "entity": "HUA",
              "entity_type": "Reason",
              "start_idx": 135,
              "end_idx": 138,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T73",
              "entity": "代谢综合征",
              "entity_type": "Disease",
              "start_idx": 154,
              "end_idx": 159,
              "entity_en": "Metabolic syndrome"
            },
            {
              "entity_id": "T74",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 160,
              "end_idx": 165,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T75",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 160,
              "end_idx": 162,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T76",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 166,
              "end_idx": 169,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T77",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 170,
              "end_idx": 175,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T78",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 170,
              "end_idx": 173,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T79",
              "entity": "慢性肾病",
              "entity_type": "Disease",
              "start_idx": 179,
              "end_idx": 183,
              "entity_en": "Chronic kidney disease"
            },
            {
              "entity_id": "T80",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 181,
              "end_idx": 182,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T81",
              "entity": "HUA",
              "entity_type": "Reason",
              "start_idx": 200,
              "end_idx": 203,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T82",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 204,
              "end_idx": 206,
              "entity_en": "gout"
            },
            {
              "entity_id": "T83",
              "entity": "痛风性关节炎",
              "entity_type": "Disease",
              "start_idx": 224,
              "end_idx": 230,
              "entity_en": "Gouty arthritis"
            },
            {
              "entity_id": "T84",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 236,
              "end_idx": 239,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T85",
              "entity": "关节",
              "entity_type": "Anatomy",
              "start_idx": 227,
              "end_idx": 229,
              "entity_en": "joint"
            },
            {
              "entity_id": "T86",
              "entity": "超过饱和浓度",
              "entity_type": "Test_Value",
              "start_idx": 19,
              "end_idx": 25,
              "entity_en": "Exceeding saturation concentration"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R18",
              "head_entity_id": "T63",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R19",
              "head_entity_id": "T64",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R20",
              "head_entity_id": "T65",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R21",
              "head_entity_id": "T66",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R22",
              "head_entity_id": "T68",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R23",
              "head_entity_id": "T69",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R24",
              "head_entity_id": "T70",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R25",
              "head_entity_id": "T71",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R26",
              "head_entity_id": "T72",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R27",
              "head_entity_id": "T72",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R28",
              "head_entity_id": "T72",
              "tail_entity_id": "T76"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R29",
              "head_entity_id": "T72",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R30",
              "head_entity_id": "T72",
              "tail_entity_id": "T79"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R31",
              "head_entity_id": "T75",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R32",
              "head_entity_id": "T78",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R33",
              "head_entity_id": "T81",
              "tail_entity_id": "T82"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R34",
              "head_entity_id": "T85",
              "tail_entity_id": "T83"
            }
          ],
          "sentence_en": "The harmfulness of HUA is receiving more and more attention. When the blood uric acid exceeds the saturation concentration, urate crystals precipitate and can directly adhere to and deposit in joints and surrounding soft tissues, renal tubules and blood vessels, and chemotactic neutrophils and macrophages; after the cells interact with the crystals, they release inflammatory factors, metalloproteinase 9, hydrolases, etc., leading to acute and chronic inflammatory damage to articular cartilage, bone, kidneys, and vascular endothelium. Therefore, HUA is generally considered to be an independent risk factor for multiple cardiovascular risk factors and related diseases (metabolic syndrome, type 2 diabetes, hypertension, cardiovascular events and death, chronic kidney disease, etc.). The consensus clearly points out that HUA is the most important biochemical basis and the most direct cause of gout. Patients with gouty arthritis should first follow the HUA management principles."
        }
      ],
      "paragraph_en": "The harmfulness of HUA is receiving more and more attention. When the blood uric acid exceeds the saturation concentration, urate crystals precipitate and can directly adhere to and deposit in joints and surrounding soft tissues, renal tubules and blood vessels, and chemotactic neutrophils and macrophages; after the cells interact with the crystals, they release inflammatory factors, metalloproteinase 9, hydrolases, etc., leading to acute and chronic inflammatory damage to articular cartilage, bone, kidneys, and vascular endothelium. Therefore, HUA is generally considered to be an independent risk factor for multiple cardiovascular risk factors and related diseases (metabolic syndrome, type 2 diabetes, hypertension, cardiovascular events and death, chronic kidney disease, etc.). The consensus clearly points out that HUA is the most important biochemical basis and the most direct cause of gout. Patients with gouty arthritis should first follow the HUA management principles."
    },
    {
      "paragraph_id": "11",
      "paragraph": "HUA和痛风的多学科联合诊治",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "HUA和痛风的多学科联合诊治",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T87",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T88",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "gout"
            }
          ],
          "relations": [],
          "sentence_en": "Multidisciplinary diagnosis and treatment of HUA and gout"
        }
      ],
      "paragraph_en": "Multidisciplinary diagnosis and treatment of HUA and gout"
    },
    {
      "paragraph_id": "12",
      "paragraph": "本共识特别强调在HUA以及痛风患者治疗过程中必须做到多学科联合治疗。(1)应关注高危人群：高龄男性、肥胖、一级亲属中有痛风史者、患有心血管疾病、肾脏疾病人群，应定期监测血清血尿酸(SUA)浓度。同时尽量避免各种危险因素因素；饮食因素、其他疾病治疗过程中的药物因素如小剂量阿司匹林、利尿剂，环孢素A、麦考酚酯、吡嗪酰胺、乙胺丁醇均可抑制尿酸在肾小管的排泄导致HUA。同时在高危人群中强调非药物治疗，包括正确生活方式指导。共时指出，健康饮食、戒烟限酒、坚持运动和控制体质量、大量饮水适当碱化尿液等生活方式改变可预防HUA，这些需要专科医师体验中心、营养师、慢病管理团队等多学科联合进行。(2)确诊的HUA或痛风患者应积极筛查并发症或合并症，及时制定多学科联合治疗方案：肾病患者须避免使用损害肾脏药物并定期监测肾功能；肾石症患者须碱化尿液，必要时给予溶石或手术治疗；合并高血糖、血脂紊乱、高血压者须同时积极降糖、调脂、降压治疗，尽量选择有利于尿酸排泄的药物，如对于高胆固醇血症或动脉粥样硬化合并HUA的患者，优先考虑阿托伐他汀；对于高甘油三酯血症合并HUA的患者，优先选用非诺贝特；高血压合并HUA患者降压药物优选氯沙坦、二氢吡啶类钙通道阻滞剂等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "本共识特别强调在HUA以及痛风患者治疗过程中必须做到多学科联合治疗。(1)应关注高危人群：高龄男性、肥胖、一级亲属中有痛风史者、患有心血管疾病、肾脏疾病人群，应定期监测血清血尿酸(SUA)浓度。同时尽量避免各种危险因素因素；饮食因素、其他疾病治疗过程中的药物因素如小剂量阿司匹林、利尿剂，环孢素A、麦考酚酯、吡嗪酰胺、乙胺丁醇均可抑制尿酸在肾小管的排泄导致HUA。同时在高危人群中强调非药物治疗，包括正确生活方式指导。共时指出，健康饮食、戒烟限酒、坚持运动和控制体质量、大量饮水适当碱化尿液等生活方式改变可预防HUA，这些需要专科医师体验中心、营养师、慢病管理团队等多学科联合进行。(2)确诊的HUA或痛风患者应积极筛查并发症或合并症，及时制定多学科联合治疗方案：肾病患者须避免使用损害肾脏药物并定期监测肾功能；肾石症患者须碱化尿液，必要时给予溶石或手术治疗；合并高血糖、血脂紊乱、高血压者须同时积极降糖、调脂、降压治疗，尽量选择有利于尿酸排泄的药物，如对于高胆固醇血症或动脉粥样硬化合并HUA的患者，优先考虑阿托伐他汀；对于高甘油三酯血症合并HUA的患者，优先选用非诺贝特；高血压合并HUA患者降压药物优选氯沙坦、二氢吡啶类钙通道阻滞剂等。",
          "start_idx": 0,
          "end_idx": 521,
          "entities": [
            {
              "entity_id": "T89",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T90",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "gout"
            },
            {
              "entity_id": "T91",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 52,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T92",
              "entity": "肾脏疾病",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 76,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T93",
              "entity": "血清血尿酸(SUA)",
              "entity_type": "Test_items",
              "start_idx": 84,
              "end_idx": 94,
              "entity_en": "Serum uric acid (SUA)"
            },
            {
              "entity_id": "T94",
              "entity": "饮食因素",
              "entity_type": "Reason",
              "start_idx": 112,
              "end_idx": 116,
              "entity_en": "Dietary factors"
            },
            {
              "entity_id": "T95",
              "entity": "药物因素如小剂量阿司匹林、利尿剂，环孢素A、麦考酚酯、吡嗪酰胺、乙胺丁醇",
              "entity_type": "Reason",
              "start_idx": 127,
              "end_idx": 163,
              "entity_en": "Drug factors such as low-dose aspirin, diuretics, cyclosporine A, mycophenolate mofetil, pyrazinamide, ethambutol"
            },
            {
              "entity_id": "T96",
              "entity": "抑制尿酸在肾小管的排泄",
              "entity_type": "Pathogenesis",
              "start_idx": 165,
              "end_idx": 176,
              "entity_en": "Inhibits the excretion of uric acid in the renal tubules"
            },
            {
              "entity_id": "T97",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 178,
              "end_idx": 181,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T98",
              "entity": "健康饮食",
              "entity_type": "Treatment",
              "start_idx": 214,
              "end_idx": 218,
              "entity_en": "Healthy eating"
            },
            {
              "entity_id": "T99",
              "entity": "戒烟限酒",
              "entity_type": "Treatment",
              "start_idx": 219,
              "end_idx": 223,
              "entity_en": "Quit smoking and limit alcohol consumption"
            },
            {
              "entity_id": "T100",
              "entity": "坚持运动",
              "entity_type": "Treatment",
              "start_idx": 224,
              "end_idx": 228,
              "entity_en": "Keep exercising"
            },
            {
              "entity_id": "T101",
              "entity": "控制体质量",
              "entity_type": "Treatment",
              "start_idx": 229,
              "end_idx": 234,
              "entity_en": "Control body mass"
            },
            {
              "entity_id": "T102",
              "entity": "大量饮水",
              "entity_type": "Treatment",
              "start_idx": 235,
              "end_idx": 239,
              "entity_en": "Drink plenty of water"
            },
            {
              "entity_id": "T103",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 255,
              "end_idx": 258,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T104",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 297,
              "end_idx": 300,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T105",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 301,
              "end_idx": 303,
              "entity_en": "gout"
            },
            {
              "entity_id": "T106",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 332,
              "end_idx": 334,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T107",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 332,
              "end_idx": 333,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T108",
              "entity": "肾石",
              "entity_type": "Disease",
              "start_idx": 356,
              "end_idx": 358,
              "entity_en": "Kidney stones"
            },
            {
              "entity_id": "T109",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 356,
              "end_idx": 357,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T110",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 382,
              "end_idx": 385,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T111",
              "entity": "血脂紊乱",
              "entity_type": "Disease",
              "start_idx": 386,
              "end_idx": 390,
              "entity_en": "Dyslipidemia"
            },
            {
              "entity_id": "T112",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 391,
              "end_idx": 394,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T113",
              "entity": "正确生活方式指导",
              "entity_type": "Treatment",
              "start_idx": 200,
              "end_idx": 208,
              "entity_en": "Correct lifestyle guidance"
            },
            {
              "entity_id": "T114",
              "entity": "溶石",
              "entity_type": "Treatment",
              "start_idx": 372,
              "end_idx": 374,
              "entity_en": "karst"
            },
            {
              "entity_id": "T115",
              "entity": "高胆固醇血症",
              "entity_type": "Disease",
              "start_idx": 429,
              "end_idx": 435,
              "entity_en": "Hypercholesterolemia"
            },
            {
              "entity_id": "T116",
              "entity": "动脉粥样硬化",
              "entity_type": "Disease",
              "start_idx": 436,
              "end_idx": 442,
              "entity_en": "Atherosclerosis"
            },
            {
              "entity_id": "T117",
              "entity": "阿托伐他汀",
              "entity_type": "Drug",
              "start_idx": 455,
              "end_idx": 460,
              "entity_en": "Atorvastatin"
            },
            {
              "entity_id": "T118",
              "entity": "高甘油三酯血症",
              "entity_type": "Disease",
              "start_idx": 463,
              "end_idx": 470,
              "entity_en": "Hypertriglyceridemia"
            },
            {
              "entity_id": "T119",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 472,
              "end_idx": 475,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T120",
              "entity": "非诺贝特",
              "entity_type": "Drug",
              "start_idx": 483,
              "end_idx": 487,
              "entity_en": "Fenofibrate"
            },
            {
              "entity_id": "T121",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 488,
              "end_idx": 491,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T122",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 493,
              "end_idx": 496,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T123",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 61,
              "entity_en": "gout"
            },
            {
              "entity_id": "T124",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 71,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T125",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 66,
              "end_idx": 69,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T126",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 72,
              "end_idx": 74,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T127",
              "entity": "监测肾功能",
              "entity_type": "Test",
              "start_idx": 350,
              "end_idx": 355,
              "entity_en": "Monitoring renal function"
            },
            {
              "entity_id": "T128",
              "entity": "氯沙坦",
              "entity_type": "Drug",
              "start_idx": 504,
              "end_idx": 507,
              "entity_en": "Losartan"
            },
            {
              "entity_id": "T129",
              "entity": "二氢吡啶类钙通道阻滞剂",
              "entity_type": "Drug",
              "start_idx": 508,
              "end_idx": 519,
              "entity_en": "Dihydropyridine calcium channel blockers"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R35",
              "head_entity_id": "T126",
              "tail_entity_id": "T92"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R36",
              "head_entity_id": "T94",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R37",
              "head_entity_id": "T95",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R38",
              "head_entity_id": "T96",
              "tail_entity_id": "T97"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R39",
              "head_entity_id": "T98",
              "tail_entity_id": "T103"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R40",
              "head_entity_id": "T99",
              "tail_entity_id": "T103"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R41",
              "head_entity_id": "T100",
              "tail_entity_id": "T103"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R42",
              "head_entity_id": "T101",
              "tail_entity_id": "T103"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R43",
              "head_entity_id": "T102",
              "tail_entity_id": "T103"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R44",
              "head_entity_id": "T107",
              "tail_entity_id": "T106"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R45",
              "head_entity_id": "T127",
              "tail_entity_id": "T106"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R46",
              "head_entity_id": "T109",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R47",
              "head_entity_id": "T114",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R48",
              "head_entity_id": "T117",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R49",
              "head_entity_id": "T117",
              "tail_entity_id": "T116"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R50",
              "head_entity_id": "T120",
              "tail_entity_id": "T118"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R51",
              "head_entity_id": "T120",
              "tail_entity_id": "T119"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R52",
              "head_entity_id": "T128",
              "tail_entity_id": "T121"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R53",
              "head_entity_id": "T129",
              "tail_entity_id": "T121"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R54",
              "head_entity_id": "T128",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R55",
              "head_entity_id": "T129",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R56",
              "head_entity_id": "T125",
              "tail_entity_id": "T124"
            }
          ],
          "sentence_en": "This consensus particularly emphasizes that multidisciplinary treatment must be implemented in the treatment of HUA and gout patients. (1) Attention should be paid to high-risk groups: elderly men, obese people, first-degree relatives with a history of gout, people with cardiovascular disease, and people with kidney disease. Serum uric acid (SUA) concentration should be monitored regularly. At the same time, various risk factors should be avoided as much as possible; dietary factors and drug factors in the treatment of other diseases, such as low-dose aspirin, diuretics, cyclosporine A, mycophenolate mofetil, pyrazinamide, and ethambutol, can inhibit the excretion of uric acid in the renal tubules and cause HUA. At the same time, non-drug treatment is emphasized in high-risk groups, including guidance on a correct lifestyle. At the same time, it is pointed out that lifestyle changes such as healthy diet, smoking cessation and alcohol restriction, exercise and weight control, drinking plenty of water and appropriate alkalinization of urine can prevent HUA. These require multidisciplinary cooperation such as specialist physician experience centers, nutritionists, and chronic disease management teams. (2) Patients with confirmed HUA or gout should be screened for complications or comorbidities and a multidisciplinary treatment plan should be formulated in a timely manner: patients with kidney disease should avoid using drugs that damage the kidneys and monitor renal function regularly; patients with nephrolithiasis should alkalinize their urine and, if necessary, receive lithotripsy or surgical treatment; patients with combined hyperglycemia, dyslipidemia, and hypertension should receive active glucose-lowering, lipid-lowering, and antihypertensive treatments, and should try to choose drugs that are beneficial to uric acid excretion. For example, for patients with hypercholesterolemia or atherosclerosis combined with HUA, atorvastatin is preferred; for patients with hypertriglyceridemia combined with HUA, fenofibrate is preferred; and for patients with hypertension combined with HUA, losartan, dihydropyridine calcium channel blockers, etc. are preferred antihypertensive drugs."
        }
      ],
      "paragraph_en": "This consensus particularly emphasizes that multidisciplinary treatment must be implemented in the treatment of HUA and gout patients. (1) Attention should be paid to high-risk groups: elderly men, obese people, first-degree relatives with a history of gout, people with cardiovascular disease, and people with kidney disease. Serum uric acid (SUA) concentration should be monitored regularly. At the same time, various risk factors should be avoided as much as possible; dietary factors and drug factors in the treatment of other diseases, such as low-dose aspirin, diuretics, cyclosporine A, mycophenolate mofetil, pyrazinamide, and ethambutol, can inhibit the excretion of uric acid in the renal tubules and cause HUA. At the same time, non-drug treatment is emphasized in high-risk groups, including guidance on a correct lifestyle. At the same time, it is pointed out that lifestyle changes such as healthy diet, smoking cessation and alcohol restriction, exercise and weight control, drinking plenty of water and appropriate alkalinization of urine can prevent HUA. These require multidisciplinary cooperation such as specialist physician experience centers, nutritionists, and chronic disease management teams. (2) Patients with confirmed HUA or gout should be screened for complications or comorbidities and a multidisciplinary treatment plan should be formulated in a timely manner: patients with kidney disease should avoid using drugs that damage the kidneys and monitor renal function regularly; patients with nephrolithiasis should alkalinize their urine and, if necessary, receive lithotripsy or surgical treatment; patients with combined hyperglycemia, dyslipidemia, and hypertension should receive active glucose-lowering, lipid-lowering, and antihypertensive treatments, and should try to choose drugs that are beneficial to uric acid excretion. For example, for patients with hypercholesterolemia or atherosclerosis combined with HUA, atorvastatin is preferred; for patients with hypertriglyceridemia combined with HUA, fenofibrate is preferred; and for patients with hypertension combined with HUA, losartan, dihydropyridine calcium channel blockers, etc. are preferred antihypertensive drugs."
    },
    {
      "paragraph_id": "13",
      "paragraph": "降尿酸治疗的起点和目标值",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "降尿酸治疗的起点和目标值",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [],
          "relations": [],
          "sentence_en": "Starting point and target value of uric acid-lowering therapy"
        }
      ],
      "paragraph_en": "Starting point and target value of uric acid-lowering therapy"
    },
    {
      "paragraph_id": "14",
      "paragraph": "共识在总结国内外痛风治疗指南和大量痛风及HUA治疗临床研究的基础上，对降尿酸药物治疗的指征、SUA控制的目标以及药物的选择给出了清晰的建议。并强调了痛风治疗的长期性和SUA定期复查的重要性。HUA的治疗应根据不同的危险因素进行分层管理。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "共识在总结国内外痛风治疗指南和大量痛风及HUA治疗临床研究的基础上，对降尿酸药物治疗的指征、SUA控制的目标以及药物的选择给出了清晰的建议。并强调了痛风治疗的长期性和SUA定期复查的重要性。",
          "start_idx": 0,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T130",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "gout"
            },
            {
              "entity_id": "T131",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "gout"
            },
            {
              "entity_id": "T132",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T133",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 76,
              "entity_en": "gout"
            },
            {
              "entity_id": "T135",
              "entity": "SUA",
              "entity_type": "Test_items",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "SUA"
            },
            {
              "entity_id": "T136",
              "entity": "SUA",
              "entity_type": "Test_items",
              "start_idx": 83,
              "end_idx": 86,
              "entity_en": "SUA"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R57",
              "head_entity_id": "T135",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R58",
              "head_entity_id": "T135",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R59",
              "head_entity_id": "T136",
              "tail_entity_id": "T133"
            }
          ],
          "sentence_en": "Based on the summary of gout treatment guidelines at home and abroad and a large number of clinical studies on gout and HUA treatment, the consensus provides clear suggestions on the indications of uric acid-lowering drug treatment, the goals of SUA control, and the selection of drugs. It also emphasizes the importance of long-term gout treatment and regular SUA review."
        },
        {
          "sentence_id": "1",
          "sentence": "HUA的治疗应根据不同的危险因素进行分层管理。",
          "start_idx": 95,
          "end_idx": 118,
          "entities": [
            {
              "entity_id": "T134",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "The treatment of HUA should be stratified according to different risk factors."
        }
      ],
      "paragraph_en": "Based on the summary of gout treatment guidelines at home and abroad and a large number of clinical studies on gout and HUA treatment, the consensus provides clear suggestions on the indications for uric acid-lowering drug treatment, the goals of SUA control, and the selection of drugs. It also emphasizes the importance of long-term gout treatment and regular SUA review. The treatment of HUA should be stratified according to different risk factors."
    },
    {
      "paragraph_id": "16",
      "paragraph": "共识指出对HUA和痛风患者，在尿酸测定之后，必须要针对患者的具体情况进行评估，不同的尿酸水平在不同的人群对器官的损害水平是不同的。在治疗上遵循个体化、分层、达标、长程管理的原则，逐步调整剂量以避免短期内血尿酸水平波动过大诱发痛风急性发作。共识指出应该根据患者SUA水平的不同和是否合并心血管危险因素或心血管及代谢性疾病的状态给予积极的分层治疗；在今后的临床实践中灵活应用，可有效预防和降低HUA对机体各脏器的危害。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "共识指出对HUA和痛风患者，在尿酸测定之后，必须要针对患者的具体情况进行评估，不同的尿酸水平在不同的人群对器官的损害水平是不同的。在治疗上遵循个体化、分层、达标、长程管理的原则，逐步调整剂量以避免短期内血尿酸水平波动过大诱发痛风急性发作。共识指出应该根据患者SUA水平的不同和是否合并心血管危险因素或心血管及代谢性疾病的状态给予积极的分层治疗；在今后的临床实践中灵活应用，可有效预防和降低HUA对机体各脏器的危害。",
          "start_idx": 0,
          "end_idx": 207,
          "entities": [
            {
              "entity_id": "T137",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T138",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "gout"
            },
            {
              "entity_id": "T139",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T140",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T141",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 104,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T142",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 112,
              "end_idx": 114,
              "entity_en": "gout"
            },
            {
              "entity_id": "T143",
              "entity": "SUA",
              "entity_type": "Test_items",
              "start_idx": 129,
              "end_idx": 132,
              "entity_en": "SUA"
            },
            {
              "entity_id": "T144",
              "entity": "心血管及代谢性疾病",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 159,
              "entity_en": "Cardiovascular and metabolic diseases"
            },
            {
              "entity_id": "T145",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 194,
              "end_idx": 197,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T146",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 150,
              "end_idx": 153,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R60",
              "head_entity_id": "T139",
              "tail_entity_id": "T137"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R61",
              "head_entity_id": "T139",
              "tail_entity_id": "T138"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R62",
              "head_entity_id": "T141",
              "tail_entity_id": "T142"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R63",
              "head_entity_id": "T143",
              "tail_entity_id": "T144"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R64",
              "head_entity_id": "T146",
              "tail_entity_id": "T144"
            }
          ],
          "sentence_en": "The consensus points out that for HUA and gout patients, after the uric acid test, the specific conditions of the patients must be evaluated. Different uric acid levels have different levels of damage to organs in different populations. In terms of treatment, the principles of individualization, stratification, reaching the target, and long-term management should be followed, and the dose should be gradually adjusted to avoid excessive fluctuations in blood uric acid levels in the short term, which may induce acute gout attacks. The consensus points out that active stratified treatment should be given according to the different SUA levels of patients and whether they have cardiovascular risk factors or cardiovascular and metabolic diseases. Flexible application in future clinical practice can effectively prevent and reduce the harm of HUA to various organs of the body."
        }
      ],
      "paragraph_en": "The consensus points out that for HUA and gout patients, after the uric acid test, the specific conditions of the patients must be evaluated. Different uric acid levels have different levels of damage to organs in different populations. In terms of treatment, the principles of individualization, stratification, reaching the target, and long-term management should be followed, and the dose should be gradually adjusted to avoid excessive fluctuations in blood uric acid levels in the short term, which may induce acute gout attacks. The consensus points out that active stratified treatment should be given according to the different SUA levels of patients and whether they have cardiovascular risk factors or cardiovascular and metabolic diseases. Flexible application in future clinical practice can effectively prevent and reduce the harm of HUA to various organs of the body."
    },
    {
      "paragraph_id": "17",
      "paragraph": "降尿酸药物的选择",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "降尿酸药物的选择",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [],
          "relations": [],
          "sentence_en": "Choice of uric acid-lowering drugs"
        }
      ],
      "paragraph_en": "Choice of uric acid-lowering drugs"
    },
    {
      "paragraph_id": "18",
      "paragraph": "共识分别对目前临床上使用的两类降尿酸药物：抑制尿酸合成的药物和促进尿酸排泄的药物进行了详细的介绍，包括起始剂量、最大剂量以及在肾功能不全患者中的使用情况。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "共识分别对目前临床上使用的两类降尿酸药物：抑制尿酸合成的药物和促进尿酸排泄的药物进行了详细的介绍，包括起始剂量、最大剂量以及在肾功能不全患者中的使用情况。",
          "start_idx": 0,
          "end_idx": 77,
          "entities": [
            {
              "entity_id": "T147",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 63,
              "end_idx": 68,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T148",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 63,
              "end_idx": 64,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R65",
              "head_entity_id": "T148",
              "tail_entity_id": "T147"
            }
          ],
          "sentence_en": "The consensus provides a detailed introduction to the two types of uric acid-lowering drugs currently used in clinical practice: drugs that inhibit uric acid synthesis and drugs that promote uric acid excretion, including the starting dose, maximum dose, and use in patients with renal insufficiency."
        }
      ],
      "paragraph_en": "The consensus provides a detailed introduction to the two types of uric acid-lowering drugs currently used in clinical practice: drugs that inhibit uric acid synthesis and drugs that promote uric acid excretion, including the starting dose, maximum dose, and use in patients with renal insufficiency."
    },
    {
      "paragraph_id": "19",
      "paragraph": "特别提到使用过程中需注意药物不良反应，强调亚裔人群使用别嘌呤醇时发生严重超敏反应的风险明显高于白种人。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "特别提到使用过程中需注意药物不良反应，强调亚裔人群使用别嘌呤醇时发生严重超敏反应的风险明显高于白种人。",
          "start_idx": 0,
          "end_idx": 51,
          "entities": [
            {
              "entity_id": "T149",
              "entity": "嘌呤醇",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "Purinol"
            },
            {
              "entity_id": "T150",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 36,
              "end_idx": 40,
              "entity_en": "Hypersensitivity reactions"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R66",
              "head_entity_id": "T150",
              "tail_entity_id": "T149"
            }
          ],
          "sentence_en": "It is particularly mentioned that attention should be paid to adverse drug reactions during use, and it is emphasized that the risk of severe hypersensitivity reactions when using allopurinol in Asian people is significantly higher than that in Caucasians."
        }
      ],
      "paragraph_en": "It is particularly mentioned that attention should be paid to adverse drug reactions during use, and it is emphasized that the risk of severe hypersensitivity reactions when using allopurinol in Asian people is significantly higher than that in Caucasians."
    },
    {
      "paragraph_id": "20",
      "paragraph": "共识还对近年来国外上市的尿酸酶以及降尿酸药物的联合使用等做了简要述评，给出适用情况及可能的不良反应。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "共识还对近年来国外上市的尿酸酶以及降尿酸药物的联合使用等做了简要述评，给出适用情况及可能的不良反应。",
          "start_idx": 0,
          "end_idx": 50,
          "entities": [
            {
              "entity_id": "T151",
              "entity": "尿酸酶",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "Uricase"
            }
          ],
          "relations": [],
          "sentence_en": "The consensus also briefly reviews the combined use of uricase and uric acid-lowering drugs that have been launched overseas in recent years, and provides applicable situations and possible adverse reactions."
        }
      ],
      "paragraph_en": "The consensus also briefly reviews the combined use of uricase and uric acid-lowering drugs that have been launched overseas in recent years, and provides applicable situations and possible adverse reactions."
    },
    {
      "paragraph_id": "21",
      "paragraph": "HUA在中国呈现高流行、年轻化趋势，同时HUA也是多种心血管事件危险因素及相关疾病的独立危险因素，本共识是我国首个HUA相关疾病的多学科专家共识，强调从系统医学角度全面认识该疾病，结合中国国情和国内诊疗实践特点，多学科协作、内外兼治，连续、全程、系统地管控HUA及其相关疾病，对HUA的诊断标准、药物选择、控制目标及预防的核心策略均给予明确阐述，对中国HUA的规范化管理具有积极的推动意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "HUA在中国呈现高流行、年轻化趋势，同时HUA也是多种心血管事件危险因素及相关疾病的独立危险因素，本共识是我国首个HUA相关疾病的多学科专家共识，强调从系统医学角度全面认识该疾病，结合中国国情和国内诊疗实践特点，多学科协作、内外兼治，连续、全程、系统地管控HUA及其相关疾病，对HUA的诊断标准、药物选择、控制目标及预防的核心策略均给予明确阐述，对中国HUA的规范化管理具有积极的推动意义。",
          "start_idx": 0,
          "end_idx": 195,
          "entities": [
            {
              "entity_id": "T152",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T153",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T154",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T155",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T156",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T157",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 128,
              "end_idx": 131,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T158",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 139,
              "end_idx": 142,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T159",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 176,
              "end_idx": 179,
              "entity_en": "HUA"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R67",
              "head_entity_id": "T155",
              "tail_entity_id": "T154"
            }
          ],
          "sentence_en": "HUA is highly prevalent and is occurring at a younger age in China. At the same time, HUA is also an independent risk factor for multiple cardiovascular risk factors and related diseases. This consensus is the first multidisciplinary expert consensus on HUA-related diseases in my country. It emphasizes a comprehensive understanding of the disease from a systems medicine perspective, combining China's national conditions and the characteristics of domestic diagnosis and treatment practices, multidisciplinary collaboration, both internal and external treatment, and continuous, full-process, and systematic management of HUA and its related diseases. It also clearly explains the diagnostic criteria, drug selection, control targets, and core prevention strategies for HUA, which has a positive driving significance for the standardized management of HUA in China."
        }
      ],
      "paragraph_en": "HUA is highly prevalent and is occurring at a younger age in China. At the same time, HUA is also an independent risk factor for multiple cardiovascular risk factors and related diseases. This consensus is the first multidisciplinary expert consensus on HUA-related diseases in my country. It emphasizes a comprehensive understanding of the disease from a systems medicine perspective, combining China's national conditions and the characteristics of domestic diagnosis and treatment practices, multidisciplinary collaboration, both internal and external treatment, and continuous, full-process, and systematic management of HUA and its related diseases. It also clearly explains the diagnostic criteria, drug selection, control targets, and core prevention strategies for HUA, which has a positive driving significance for the standardized management of HUA in China."
    },
    {
      "paragraph_id": "15",
      "paragraph": "共识根据痛风是否发作、危险因素、SUA浓度等分为三种情况：第一种情况是当有痛风发作且发作频繁时(≥2次)或者痛风性关节炎只发作1次，但合并有其他相关危险因素(年龄<40岁、有痛风石或关节腔尿酸盐沉积证据、尿酸性肾结石或肾功能损害≥G2期、高血压、糖尿病、血脂异常、肥胖、卒中、冠心病、心力衰竭)中的—项，不论尿酸水平如何，都需要进行降尿酸治疗，尿酸控制目标值应<360μmol/L，如果出现痛风石、慢性痛风性关节炎、痛风性关节炎发作频繁，患者尿酸控制目标值应<300μmol/L；第二种情况是痛风性关节炎只发作1次，或者没有急性发作但合并有其他相关危险因素(尿酸性肾结石或肾功能损害≥G2期、高血压、糖尿病、血脂异常、卒中、冠心病、肥胖、心力衰竭)，当尿酸浓度超过480μmol/L，应启动降尿酸治疗，尿酸控制目标值同第一种况；第三种情况是如果没有危险因素，也没有痛风发作，但尿酸>540μmol/L，也建议启动降尿酸治疗，尿酸控制目标值应<420μmol/L。共识指出，这三种情况都不应将血尿酸降至180μmol/L以下。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "共识根据痛风是否发作、危险因素、SUA浓度等分为三种情况：第一种情况是当有痛风发作且发作频繁时(≥2次)或者痛风性关节炎只发作1次，但合并有其他相关危险因素(年龄<40岁、有痛风石或关节腔尿酸盐沉积证据、尿酸性肾结石或肾功能损害≥G2期、高血压、糖尿病、血脂异常、肥胖、卒中、冠心病、心力衰竭)中的—项，不论尿酸水平如何，都需要进行降尿酸治疗，尿酸控制目标值应<360μmol/L，如果出现痛风石、慢性痛风性关节炎、痛风性关节炎发作频繁，患者尿酸控制目标值应<300μmol/L；第二种情况是痛风性关节炎只发作1次，或者没有急性发作但合并有其他相关危险因素(尿酸性肾结石或肾功能损害≥G2期、高血压、糖尿病、血脂异常、卒中、冠心病、肥胖、心力衰竭)，当尿酸浓度超过480μmol/L，应启动降尿酸治疗，尿酸控制目标值同第一种况；第三种情况是如果没有危险因素，也没有痛风发作，但尿酸>540μmol/L，也建议启动降尿酸治疗，尿酸控制目标值应<420μmol/L。",
          "start_idx": 0,
          "end_idx": 431,
          "entities": [
            {
              "entity_id": "T160",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "gout"
            },
            {
              "entity_id": "T161",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 39,
              "entity_en": "gout"
            },
            {
              "entity_id": "T162",
              "entity": "SUA",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "SUA"
            },
            {
              "entity_id": "T163",
              "entity": "痛风性关节炎",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 60,
              "entity_en": "Gouty arthritis"
            },
            {
              "entity_id": "T164",
              "entity": "关节",
              "entity_type": "Anatomy",
              "start_idx": 57,
              "end_idx": 59,
              "entity_en": "joint"
            },
            {
              "entity_id": "T165",
              "entity": "尿酸性肾结石",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 108,
              "entity_en": "Uric acid kidney stones"
            },
            {
              "entity_id": "T166",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 106,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T167",
              "entity": "肾功能损害≥G2期",
              "entity_type": "Disease",
              "start_idx": 109,
              "end_idx": 118,
              "entity_en": "Renal impairment ≥ G2"
            },
            {
              "entity_id": "T168",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 109,
              "end_idx": 110,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T169",
              "entity": "G2期",
              "entity_type": "Class",
              "start_idx": 115,
              "end_idx": 118,
              "entity_en": "G2"
            },
            {
              "entity_id": "T170",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 119,
              "end_idx": 122,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T171",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 123,
              "end_idx": 126,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T172",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 131,
              "entity_en": "Dyslipidemia"
            },
            {
              "entity_id": "T173",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 132,
              "end_idx": 134,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T174",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 135,
              "end_idx": 137,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T175",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 138,
              "end_idx": 141,
              "entity_en": "Coronary heart disease"
            },
            {
              "entity_id": "T176",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 139,
              "end_idx": 140,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T177",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 146,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T178",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 142,
              "end_idx": 143,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T179",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 154,
              "end_idx": 156,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T180",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 172,
              "end_idx": 174,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T181",
              "entity": "<360μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 180,
              "end_idx": 190,
              "entity_en": "<360μmol/L"
            },
            {
              "entity_id": "T182",
              "entity": "痛风石",
              "entity_type": "Disease",
              "start_idx": 195,
              "end_idx": 198,
              "entity_en": "Tophi"
            },
            {
              "entity_id": "T183",
              "entity": "慢性痛风性关节炎",
              "entity_type": "Disease",
              "start_idx": 199,
              "end_idx": 207,
              "entity_en": "Chronic gouty arthritis"
            },
            {
              "entity_id": "T184",
              "entity": "关节",
              "entity_type": "Anatomy",
              "start_idx": 204,
              "end_idx": 206,
              "entity_en": "joint"
            },
            {
              "entity_id": "T185",
              "entity": "痛风性关节炎",
              "entity_type": "Disease",
              "start_idx": 208,
              "end_idx": 214,
              "entity_en": "Gouty arthritis"
            },
            {
              "entity_id": "T186",
              "entity": "关节",
              "entity_type": "Anatomy",
              "start_idx": 211,
              "end_idx": 213,
              "entity_en": "joint"
            },
            {
              "entity_id": "T187",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 221,
              "end_idx": 223,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T188",
              "entity": "<300μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 229,
              "end_idx": 239,
              "entity_en": "<300 μmol/L"
            },
            {
              "entity_id": "T189",
              "entity": "痛风性关节炎",
              "entity_type": "Disease",
              "start_idx": 246,
              "end_idx": 252,
              "entity_en": "Gouty arthritis"
            },
            {
              "entity_id": "T190",
              "entity": "关节",
              "entity_type": "Anatomy",
              "start_idx": 249,
              "end_idx": 251,
              "entity_en": "joint"
            },
            {
              "entity_id": "T191",
              "entity": "尿酸性肾结石",
              "entity_type": "Disease",
              "start_idx": 279,
              "end_idx": 285,
              "entity_en": "Uric acid kidney stones"
            },
            {
              "entity_id": "T192",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 282,
              "end_idx": 283,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T193",
              "entity": "肾功能损害≥G2期",
              "entity_type": "Disease",
              "start_idx": 286,
              "end_idx": 295,
              "entity_en": "Renal impairment ≥ G2"
            },
            {
              "entity_id": "T194",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 286,
              "end_idx": 287,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T195",
              "entity": "G2期",
              "entity_type": "Class",
              "start_idx": 292,
              "end_idx": 295,
              "entity_en": "G2"
            },
            {
              "entity_id": "T196",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 296,
              "end_idx": 299,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T197",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 300,
              "end_idx": 303,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T198",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 304,
              "end_idx": 308,
              "entity_en": "Dyslipidemia"
            },
            {
              "entity_id": "T199",
              "entity": "卒中",
              "entity_type": "Disease",
              "start_idx": 309,
              "end_idx": 311,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T200",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 312,
              "end_idx": 315,
              "entity_en": "Coronary heart disease"
            },
            {
              "entity_id": "T201",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 313,
              "end_idx": 314,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T202",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 316,
              "end_idx": 318,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T203",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 319,
              "end_idx": 323,
              "entity_en": "Heart failure"
            },
            {
              "entity_id": "T204",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 326,
              "end_idx": 328,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T205",
              "entity": "超过480μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 330,
              "end_idx": 341,
              "entity_en": "More than 480 μmol/L"
            },
            {
              "entity_id": "T206",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 351,
              "end_idx": 353,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T207",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 382,
              "end_idx": 384,
              "entity_en": "gout"
            },
            {
              "entity_id": "T208",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 388,
              "end_idx": 390,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T209",
              "entity": ">540μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 390,
              "end_idx": 400,
              "entity_en": ">540μmol/L"
            },
            {
              "entity_id": "T210",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 412,
              "end_idx": 414,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T211",
              "entity": "<420μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 420,
              "end_idx": 430,
              "entity_en": "<420μmol/L"
            },
            {
              "entity_id": "T214",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 319,
              "end_idx": 320,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T215",
              "entity": "痛风石",
              "entity_type": "Disease",
              "start_idx": 87,
              "end_idx": 90,
              "entity_en": "Tophi"
            },
            {
              "entity_id": "T216",
              "entity": "关节腔尿酸盐沉积",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 99,
              "entity_en": "Urate deposition in joint cavity"
            },
            {
              "entity_id": "T217",
              "entity": "关节腔",
              "entity_type": "Anatomy",
              "start_idx": 91,
              "end_idx": 94,
              "entity_en": "Joint cavity"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R68",
              "head_entity_id": "T162",
              "tail_entity_id": "T160"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R69",
              "head_entity_id": "T179",
              "tail_entity_id": "T160"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R70",
              "head_entity_id": "T164",
              "tail_entity_id": "T163"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R71",
              "head_entity_id": "T166",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R72",
              "head_entity_id": "T168",
              "tail_entity_id": "T167"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R73",
              "head_entity_id": "T169",
              "tail_entity_id": "T167"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R74",
              "head_entity_id": "T176",
              "tail_entity_id": "T175"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R75",
              "head_entity_id": "T178",
              "tail_entity_id": "T177"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R76",
              "head_entity_id": "T184",
              "tail_entity_id": "T183"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R77",
              "head_entity_id": "T186",
              "tail_entity_id": "T185"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R78",
              "head_entity_id": "T190",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R79",
              "head_entity_id": "T204",
              "tail_entity_id": "T189"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R80",
              "head_entity_id": "T192",
              "tail_entity_id": "T191"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R81",
              "head_entity_id": "T204",
              "tail_entity_id": "T191"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R82",
              "head_entity_id": "T194",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R83",
              "head_entity_id": "T195",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R84",
              "head_entity_id": "T204",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R85",
              "head_entity_id": "T204",
              "tail_entity_id": "T197"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R86",
              "head_entity_id": "T204",
              "tail_entity_id": "T198"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R87",
              "head_entity_id": "T204",
              "tail_entity_id": "T199"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R88",
              "head_entity_id": "T201",
              "tail_entity_id": "T200"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R89",
              "head_entity_id": "T204",
              "tail_entity_id": "T200"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R90",
              "head_entity_id": "T204",
              "tail_entity_id": "T202"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R91",
              "head_entity_id": "T214",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R92",
              "head_entity_id": "T204",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R93",
              "head_entity_id": "T208",
              "tail_entity_id": "T207"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R94",
              "head_entity_id": "T217",
              "tail_entity_id": "T216"
            }
          ],
          "sentence_en": "The consensus is divided into three situations according to whether gout occurs, risk factors, SUA concentration, etc.: the first situation is when there is frequent gout attack (≥2 times) or gouty arthritis only occurs once, but there is one of other relevant risk factors (age <40 years old, evidence of tophi or joint cavity urate deposition, uric acid kidney stones or renal function damage ≥G2 stage, hypertension, diabetes, dyslipidemia, obesity, stroke, coronary heart disease, heart failure), regardless of the uric acid level, uric acid lowering treatment is required, and the uric acid control target value should be <360μmol/L. If tophi, chronic gouty arthritis, gouty arthritis, or gouty arthritis occur, uric acid-lowering treatment is required. The first situation is that the patient has frequent gout attacks, and the patient's uric acid control target value should be <300μmol/L; the second situation is that gouty arthritis only occurs once, or there is no acute attack but there are other related risk factors (uric acid kidney stones or renal function impairment ≥G2 stage, hypertension, diabetes, dyslipidemia, stroke, coronary heart disease, obesity, heart failure). When the uric acid concentration exceeds 480μmol/L, uric acid-lowering treatment should be initiated, and the uric acid control target value is the same as the first situation; the third situation is that if there are no risk factors and no gout attacks, but the uric acid level is >540μmol/L, it is also recommended to start uric acid-lowering treatment, and the uric acid control target value should be <420μmol/L."
        },
        {
          "sentence_id": "1",
          "sentence": "共识指出，这三种情况都不应将血尿酸降至180μmol/L以下。",
          "start_idx": 431,
          "end_idx": 462,
          "entities": [
            {
              "entity_id": "T212",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T213",
              "entity": "180μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 19,
              "end_idx": 28,
              "entity_en": "180μmol/L"
            }
          ],
          "relations": [],
          "sentence_en": "The consensus points out that in none of these three situations should blood uric acid be reduced to below 180 μmol/L."
        }
      ],
      "paragraph_en": "The consensus is divided into three situations according to whether gout occurs, risk factors, SUA concentration, etc.: the first situation is when there is frequent gout attack (≥2 times) or gouty arthritis only occurs once, but there is one of other relevant risk factors (age <40 years old, evidence of tophi or joint cavity urate deposition, uric acid kidney stones or renal function damage ≥G2 stage, hypertension, diabetes, dyslipidemia, obesity, stroke, coronary heart disease, heart failure), regardless of the uric acid level, uric acid lowering treatment is required, and the uric acid control target value should be <360μmol/L. If tophi, chronic gouty arthritis, gouty arthritis, or gouty arthritis occur, uric acid-lowering treatment is required. The first case is that the patient has frequent gout attacks, and the patient's uric acid control target value should be <300μmol/L; the second case is that gouty arthritis only occurs once, or there is no acute attack but there are other related risk factors (uric acid kidney stones or renal function damage ≥G2 stage, hypertension, diabetes, dyslipidemia, stroke, coronary heart disease, obesity, heart failure). When the uric acid concentration exceeds 480μmol/L, uric acid-lowering treatment should be initiated, and the uric acid control target value is the same as the first case; the third case is that if there are no risk factors and no gout attacks, but the uric acid is >540μmol/L, it is also recommended to start uric acid-lowering treatment, and the uric acid control target value should be <420μmol/L. The consensus points out that in these three cases, blood uric acid should not be reduced to below 180μmol/L."
    },
    {
      "paragraph_id": "3",
      "paragraph": "HUA具有两层含义，一种是理化性质上的定义，另一种流行病学上的定义。既往HUA定义的依据是流行病学数据，即正常嘌呤饮食下，非同日两次空腹血尿酸水平男性>420μmol/L，女性>360μmol/L。而理化性质上的定义，也称为绝对HUA，正常人体血液pH值为7.35~7.45，处于微碱性，而尿酸在这样的酸碱环境下，浓度—H超过420 μmol/L(不分男女)，便会析出尿酸钠结晶而沉积在关节腔和其他组织中，继而引起痛风性关节炎和/或其他相关组织损伤。因此，本共识将血尿酸水平>420μmol/L定义为HUA，更具有临床意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "HUA具有两层含义，一种是理化性质上的定义，另一种流行病学上的定义。既往HUA定义的依据是流行病学数据，即正常嘌呤饮食下，非同日两次空腹血尿酸水平男性>420μmol/L，女性>360μmol/L。而理化性质上的定义，也称为绝对HUA，正常人体血液pH值为7.35~7.45，处于微碱性，而尿酸在这样的酸碱环境下，浓度—H超过420 μmol/L(不分男女)，便会析出尿酸钠结晶而沉积在关节腔和其他组织中，继而引起痛风性关节炎和/或其他相关组织损伤。",
          "start_idx": 0,
          "end_idx": 225,
          "entities": [
            {
              "entity_id": "T218",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T219",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T220",
              "entity": "空腹血尿酸",
              "entity_type": "Test_items",
              "start_idx": 66,
              "end_idx": 71,
              "entity_en": "Fasting serum uric acid"
            },
            {
              "entity_id": "T221",
              "entity": ">420μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 75,
              "end_idx": 85,
              "entity_en": ">420μmol/L"
            },
            {
              "entity_id": "T222",
              "entity": ">360μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 88,
              "end_idx": 98,
              "entity_en": ">360μmol/L"
            },
            {
              "entity_id": "T223",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 117,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T224",
              "entity": "血液pH",
              "entity_type": "Test_items",
              "start_idx": 122,
              "end_idx": 126,
              "entity_en": "Blood pH"
            },
            {
              "entity_id": "T225",
              "entity": "7.35~7.45",
              "entity_type": "Test_Value",
              "start_idx": 128,
              "end_idx": 137,
              "entity_en": "7.35~7.45"
            },
            {
              "entity_id": "T226",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 145,
              "end_idx": 147,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T227",
              "entity": "痛风性关节炎",
              "entity_type": "Disease",
              "start_idx": 207,
              "end_idx": 213,
              "entity_en": "Gouty arthritis"
            },
            {
              "entity_id": "T231",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 117,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T232",
              "entity": "尿酸钠结晶而沉积在关节腔和其他组织中",
              "entity_type": "Reason",
              "start_idx": 184,
              "end_idx": 202,
              "entity_en": "Sodium urate crystals deposited in joints and other tissues"
            },
            {
              "entity_id": "T233",
              "entity": "420 μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 163,
              "end_idx": 173,
              "entity_en": "420 μmol/L"
            },
            {
              "entity_id": "T234",
              "entity": "关节",
              "entity_type": "Anatomy",
              "start_idx": 210,
              "end_idx": 212,
              "entity_en": "joint"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R95",
              "head_entity_id": "T220",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R96",
              "head_entity_id": "T224",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R97",
              "head_entity_id": "T226",
              "tail_entity_id": "T231"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R98",
              "head_entity_id": "T232",
              "tail_entity_id": "T227"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R99",
              "head_entity_id": "T234",
              "tail_entity_id": "T227"
            }
          ],
          "sentence_en": "HUA has two meanings, one is the definition of physical and chemical properties, and the other is the definition of epidemiology. The basis for the previous definition of HUA was epidemiological data, that is, under a normal purine diet, the fasting blood uric acid level on two different days was >420μmol/L for men and >360μmol/L for women. The definition of physical and chemical properties, also known as absolute HUA, is that the normal human blood pH value is 7.35~7.45, which is slightly alkaline. In such an acid-base environment, when the concentration of uric acid exceeds 420 μmol/L (regardless of gender), sodium urate crystals will precipitate and deposit in the joint cavity and other tissues, causing gouty arthritis and/or other related tissue damage."
        },
        {
          "sentence_id": "1",
          "sentence": "因此，本共识将血尿酸水平>420μmol/L定义为HUA，更具有临床意义。",
          "start_idx": 225,
          "end_idx": 262,
          "entities": [
            {
              "entity_id": "T228",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T229",
              "entity": ">420μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 12,
              "end_idx": 22,
              "entity_en": ">420μmol/L"
            },
            {
              "entity_id": "T230",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "HUA"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R100",
              "head_entity_id": "T228",
              "tail_entity_id": "T230"
            }
          ],
          "sentence_en": "Therefore, this consensus defines a serum uric acid level >420 μmol/L as HUA, which is more clinically significant."
        }
      ],
      "paragraph_en": "HUA has two meanings, one is the definition of physical and chemical properties, and the other is the definition of epidemiology. The basis for the previous definition of HUA was epidemiological data, that is, under a normal purine diet, the fasting blood uric acid level on two different days was >420μmol/L for men and >360μmol/L for women. The definition of physical and chemical properties, also known as absolute HUA, is that the normal human blood pH value is 7.35~7.45, which is slightly alkaline. In such an acid-base environment, when the concentration of uric acid exceeds 420 μmol/L (regardless of gender), sodium urate crystals will precipitate and deposit in the joint cavity and other tissues, causing gouty arthritis and/or other related tissue damage. Therefore, this consensus defines blood uric acid levels >420μmol/L as HUA, which is more clinically meaningful."
    }
  ]
}